Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

GALECTIN THERAPEUTICS INC (GALT) Market Cap & Valuation Ratios

GALECTIN THERAPEUTICS INC (GALT) has a market cap of $321.7M, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GALTGALECTIN THERAPEUTICS INCFollow GALT — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
321.7M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
16 Nov, in 23 days

Peers

drug manufacturers - general · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
GALT0.3———————
ASMB0.4—1.1—-9.5%+125%-12%-3%
RZLT0.4——————-105%
NBP0.4———-5.6%——-587%
CTNM0.3——————-35%
TTRX0.3———-1.4%———
BNTC0.3———-5.5%———
PRLD0.3—6.2—-11.5%+220%-301%-86%
IRD0.3—24.0—-12.2%-36%——
QNRX0.3———-5.4%———
AMRN0.3———6.0%-15%-22%-13%
Median of these 10—6.2—-5.6%+55%-22%-60%

.

Growth vs. price

each dot a company · hover or tap for values

GALECTIN THERAPEUTICS INC — questions

What is GALECTIN THERAPEUTICS INC's market cap?
$321.7M.

Every figure on this page comes from GALECTIN THERAPEUTICS INC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.